Acute liver failure

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
Tuesday, March 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, EPS, Task force, DNA, Nursing care plan, Piperacillin, Noise, Corporate social responsibility, FDA, Corporation, Medicine, UN, Dow Jones, EMR, Failure, Baxter International, Growth, Perioperative, TCFD, DJSI, Patient, Tazobactam, Centrella, Skin, Thrombin, Risk, Warburg Pincus, Acute liver failure, Galaxy, PD, NuVasive, Peritoneal dialysis, Risk management, Advent International, BPS, Sale, Eye, CST, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
  • For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
  • In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
  • For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Retrieved on: 
Monday, January 8, 2024
Sciatica, Kidney, Orange Book, Pain management, Food, Migraine, LRP, Pain, FDA, Gout, CMC, Chronic pain, Injection, Patent, NDA, Health, GMP, Neurology, PALO, Medicare, Letter, PDL, Observation, Paracetamol, Growth, Pharmacy, Medicaid, Safety, Patient, MENA, Therapy, Rheumatology, NDS, Creativity, Acute liver failure, Communication, Pharmaceutical industry

PALO ALTO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today issued a letter from Jaisim Shah, its Chief Executive Officer and President, to its stockholders highlighting the Company’s accomplishments in 2023 and its forward outlook for 2024.

Key Points: 
  • PALO ALTO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today issued a letter from Jaisim Shah, its Chief Executive Officer and President, to its stockholders highlighting the Company’s accomplishments in 2023 and its forward outlook for 2024.
  • Dear Scilex Holding Company Stockholders,
    I would like to express my deepest gratitude for your unwavering support, patience, and invaluable feedback throughout the transformative year in 2023.
  • As we continue to navigate the complexities of the pharmaceutical landscape, your role as stockholders in this journey is invaluable.
  • Despite the challenges that remain ahead, we are setting ambitious goals for the Company in 2024, including:
    Expected launch of Gloperba®.

EVerZom: Therapeutic Ambition in Exosome Biotherapies

Retrieved on: 
Wednesday, December 13, 2023
Urine, RNA, Liver, Quality of life, Dicarboxylic acid, Protein, Partnership, NASH, IND, Big Pharma, Acute liver failure, Saliva, Crohn's disease, Regenerative medicine, Lung cancer, Diffusion, Blood, Doctor of Philosophy, Cirrhosis, Fistula, Accelerator, Exosome, Lipid, FedEx, CNRS, Engineering, EIC, Cell, Patient, Publication, Safety, Therapy, Pharmaceutical industry

Paris, December 13, 2023 - EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.

Key Points: 
  • Paris, December 13, 2023 - EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.
  • This revolutionary drug modality constitutes a new therapeutic era for acellular off the shelf therapeutics, opening up new opportunities in cell and gene therapy.
  • This platform addresses the entire technological value chain, from cell to patient: cell sourcing, exosome generation, engineering and formulation.
  • Leveraging its innovation platform, EVerZom’s ambition is to develop its pipeline of proprietary biotherapies in regenerative medicine, while building partnerships in several other indications.

Holiday Pet Dangers

Retrieved on: 
Wednesday, November 15, 2023
CNS, Xanthine, Holiday, Vomiting, Poisoning, Pet, Urine, Blood pressure, Cat, Toxicity, THC, Toxicology, Coma, Risk, Tremor, Arrhythmia, Chocolate, Hypoglycemia, Xylitol, Metabolic acidosis, Ataxia, New Year's Eve, Milk, Heart rate, Animal, Acute liver failure, Oxycodone, Ethanol, Hypoventilation, Friends, Alaskan Malamute, Caffeine, Seizure, Golden, Kidney failure, Diarrhea, Survival, Death, Tachycardia, Happiness, Paracetamol, Classic, Family, Nightmare, Mouth, Sodium chloride, Central nervous system, Failure, Common, Dog, Hypothermia, Lethargy, Radar, Theobromine, Fireworks, Liquor, Tourism, Makita

MINNEAPOLIS, Nov. 15, 2023 /PRNewswire/ -- The holidays are best spent with family and friends, not taking a trip to the animal hospital. With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.

Key Points: 
  • With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.
  • Meinke also contacted Pet Poison Helpline, who then worked with the medical team at BluePearl to identify the lily, diagnose and treat his pets.
  • "Many holiday treats include chocolate, and are often left sitting out on counters and dinner tables," said Dr. Schmid.
  • This year, we want pet lovers to remember the holidays for all the joy and happiness, not an emergency room visit."

Children’s Hospital Los Angeles Researchers Develop Clinical Tool to Predict if a Child in Acute Liver Failure Will Need a Transplant

Retrieved on: 
Monday, October 23, 2023
Software, Research, Internet, Family, Consumer, Apps, Applications, Technology, Hospitals, Children, Science, Surgery, Health, Liver injury, Child, Children's Hospital Los Angeles, PELD, Smartphone, Liver, MD, USC, Viral hepatitis, Cirrhosis, Doctor of Philosophy, FRCSC, MBBS, Immune-mediated inflammatory diseases, FACS, King's College Hospital NHS Foundation Trust, Division, Chronic liver disease, Risk, National Cancer Institute, CHLA, Nutrition, Probability, King's College Hospital, Hepatotoxicity, Liver failure, NIH, MHA, Hospital, Patient, Transplant, Acute liver failure, Diagnosis, Death, MS, Dietary supplement, Birth control, Gastroenterology

Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.

Key Points: 
  • Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.
  • While pediatric acute liver failure has been linked to both viral hepatitis and drug-induced liver injury, at least half of cases have no apparent trigger.
  • The CHALF Score predicts if a child experiencing acute liver failure will recover or should be referred to a transplant center.
  • Doctors do not want to refer a child for liver transplant who could otherwise recover with medical treatment—about 70% of children with acute liver failure recover while keeping their original liver.

South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain

Retrieved on: 
Thursday, October 12, 2023
Pain, Male, Priority review, Food, Female, Plasma protein binding, PAG, U.S. FDA, MD, Aes, Communication, Liver, PK, Safety, Western world, MAD, Vital signs, Paracetamol, FDA, White Light Rock & Roll Review, Collection, Accelerated approval (FDA), Kidney, NDA, Acute liver failure, Automated ECG interpretation, Fast Track, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Volunteering, CNS, Patient, Pharmaceutical industry, Medical device

NEW ORLEANS, Oct. 12, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain. SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities. The Fast Track designation facilitates the development and expedites the review of new therapies for serious conditions, aiming to bring important new drugs to patients earlier and address unmet medical needs.

Key Points: 
  • The Fast Track designation accelerates SRP-001's path to U.S. FDA submission for the treatment of acute pain
    Enhanced time-to-market delivers a therapeutic alternative to habit-forming opioids and acetaminophen, the leading cause of acute liver failure in the U.S.
    NEW ORLEANS, Oct. 12, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain.
  • SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities.
  • The Fast Track designation facilitates the development and expedites the review of new therapies for serious conditions, aiming to bring important new drugs to patients earlier and address unmet medical needs.
  • "In the CNS and pain space, Fast Track designation for SRP-001 isn't just a regulatory milestone; it's a commercial accelerant.

Acute Liver Failure Industry 2023-2032: Epidemiology, Emerging Drugs, Market Trends, and Insights from Key Opinion Leaders - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 22, 2023
Health, Pharmaceutical, KOL, PESTLE, Epidemiology, Intelligence, SWOT, Growth–share matrix, Porter's five forces analysis, Acute liver failure, United Kingdom, Growth, Dietary supplement, Pharmaceutical industry

The "Acute Liver Failure - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Liver Failure - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Key highlights of the report include:
    Acute Liver Failure Epidemiology: The report offers insights into the historical and current patient pool for Acute Liver Failure and forecasts the trend for each of the seven major countries.
  • KOL Views: Key opinion leaders' and subject matter experts' opinions are sought to validate current and emerging treatment patterns and market trends for Acute Liver Failure.
  • Overall, the report offers valuable insights into the Acute Liver Failure market, including epidemiology, treatment practices, emerging drugs, market outlook, and competitive landscape.

Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
Event, Average revenue per user, Internal Revenue Service, Research, Acute liver failure, Patient, Investment, Average cost, EDEN, FDA, Letter, IND, MIRO, Pharmaceutical industry, Cryptocurrency

EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update.

Key Points: 
  • EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update.
  • "Miromatrix remains on pace to submit a response to the FDA’s clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO.
  • Unrestricted cash and investments totaled $20.4 million as of June 30, 2023, compared to $25.6 million as of March 31, 2023.
  • The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Monday, August 14, 2023, at 4:30 PM ET.

Miromatrix Reports First Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Event, Innovation, Research, Pioneer, Acute liver failure, MED, Patient, Investment, Average cost, Cell, EDEN, FDA, Letter, IND, MIRO, Pharmaceutical industry

EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported first quarter 2023 financial results and provided a corporate update.

Key Points: 
  • EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported first quarter 2023 financial results and provided a corporate update.
  • Operating loss for the first quarter of 2023 was $8.1 million, compared to $7.2 million in the first quarter of 2022.
  • Net loss for the first quarter of 2023 was $7.5 million, or $0.33 per share, compared to $7.2 million, or $0.35 per share in the first quarter of 2022.
  • The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Thursday, May 11, 2023, at 4:30 PM ET.